Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Olomorasib with Midazolam, Digoxin, and Rosuvastatin
NCT06111521Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olomorasib in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration of LY3537982, Area Under the Concentration-Time Curve from Time 0 to Infinity of LY3537982 and 13 more. Started Oct 2023; status: completed.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06111521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111521.